Life Sciences

  • May 18, 2026

    Justices Deny Eli Lilly's Qui Tam Constitutional Challenge

    The U.S. Supreme Court on Monday declined to review Eli Lilly's $183 million trial loss to a whistleblower who claimed the drugmaker knowingly defrauded the government by underpaying Medicaid drug rebates.

  • May 18, 2026

    High Court Spurns Pharma Challenges To IRA Drug Price Talks

    The U.S. Supreme Court rejected six petitions Monday from pharmaceutical giants seeking to bring down the Medicare drug price negotiations established as part of the Inflation Reduction Act three years ago.

  • May 15, 2026

    Fed. Circ. Drops A Theme Song, Talks Guest Judges

    The Federal Circuit's full lineup came together Friday to provide practitioners with insight about their experience sitting on other courts, in a conference where the chief judge dropped the court's first (and only) single.

  • May 15, 2026

    Med Device Groups 'Overshot' In Fair Use Args, Judge Says

    A judge on a D.C. Circuit panel said a set of industry groups covering the advanced medical device industry might have "overshot" in a challenge to a Library of Congress exemption that said use of copyrighted software for the purpose of repairing those devices fell under fair use, since the groups tried to lump the software that merely operates the machines into the case.

  • May 15, 2026

    Pharmacies Stuck With CVS Arbitration Mandate At 9th Circ.

    A Ninth Circuit panel refused Friday to let four independent pharmacies avoid arbitrating their antitrust claims that CVS exploited a Medicare loophole to charge them exorbitant fees, standing by a district court's conclusion that just because parts of the arbitration agreement were unconscionable doesn't negate the entire thing.

  • May 15, 2026

    Edwards Investors Sue In Chancery Over $16.4B Stock Drop

    A stockholder has sued Edwards Lifesciences Corp.'s current and former leaders in Delaware Chancery Court, claiming they misled investors about growth prospects for the medical device company's key artificial heart valve business before a July 2024 disclosure wiped out more than $16.4 billion in shareholder value.

  • May 15, 2026

    Texas Hospital Creates 'De-Transition Clinic' After Settlement

    The Texas attorney general announced a settlement with Texas Children's Hospital that will see the creation of a detransition clinic, saying Friday that the hospital will pay $10 million for billing Texas Medicaid for "illegal 'gender-transition' interventions."

  • May 15, 2026

    4th Circ. Hands Express Scripts Jury Trial In W.Va. Opioid Suit

    The Fourth Circuit on Friday issued a writ of mandamus backing Express Scripts Inc.'s right to a jury trial in litigation over the pharmacy benefit manager's alleged role in contributing to the opioid crisis in West Virginia.

  • May 15, 2026

    Insurer Owes No Coverage In Ill. Genetic Testing Fraud Suit

    An insurer does not have to defend an embryo storage lab against a proposed class action alleging it used deceptive marketing to sell genetic testing services to IVF patients, because misleading promotion doesn't fall under the lab's coverage, an Illinois federal judge has ruled.

  • May 15, 2026

    $19.2M Joint Juice Deal Ends Calif. False Ad Suit

    A California federal judge has given final approval to a nearly $19.2 million settlement to end more than a decade of litigation alleging that the makers of Joint Juice misled consumers about its health benefits.

  • May 15, 2026

    Marketer Says It Was Pawn In Med Supplier's Crypto Pivot

    A Massachusetts marketing firm says a medical supply company used it to broker a $50 million deal with another supplier, touted the arrangement to investors, then abruptly turned itself into a cryptocurrency business, stiffing the plaintiff out of anticipated commissions.

  • May 14, 2026

    Squires Lays Out Principles For Patent Review Discretion

    U.S. Patent and Trademark Office Director John A. Squires issued a precedential decision Thursday outlining the principles underlying his discretion in instituting America Invents Act reviews, emphasizing that Congress intended such reviews to be an alternative to costly and lengthy litigation.

  • May 14, 2026

    Legislative Update: Cannabis And Psychedelics Bill Roundup

    Members of Congress approved language in a funding bill that would block the rescheduling of marijuana, Colorado lawmakers gave final approval to a bill to fund research into the psychedelic ibogaine and authorize the establishment of licensed treatment centers, and Rhode Island lawmakers introduced legislation to eliminate geographic criteria from the state's cannabis social equity program.

  • May 14, 2026

    NC Republicans Want Fetal Personhood Question On '26 Ballot

    Two Republicans in the North Carolina House who have a history of advancing so-called fetal personhood bills have made another attempt to put a constitutional amendment to voters in November to decide if life begins at fertilization.

  • May 14, 2026

    Takeda To Pay $13.6M Over Antidepressant Drug Kickbacks

    Takeda Pharmaceuticals will pay $13.6 million to end allegations that it caused false Medicaid claims by providing kickbacks to healthcare providers to push prescriptions of its antidepressant drug Trintellix, the U.S. Department of Justice announced Thursday.

  • May 14, 2026

    Human Reproduction Proves Talc Can Reach Ovaries, Jury Told

    A medical oncologist on Thursday told a Los Angeles bellwether jury considering claims that Johnson & Johnson's talc products caused three women's deadly ovarian cancer that the female reproductive system is an "open" system where talc can migrate to the ovaries, and that "we wouldn't exist" if that was not the case.

  • May 14, 2026

    Squires Walks Back 5 More IPR Grants Over Inconsistent Args

    U.S. Patent and Trademark Office Director John Squires has reversed earlier decisions granting five petitions for patent review, citing what he called the challengers' inconsistent positions in parallel proceedings and explaining that four petitions he denied in previous bulk orders were also rejected for the same reasons. 

  • May 14, 2026

    House Passes Bill To Narrow Biofuel Blending Exemption

    The U.S. House of Representatives has passed a bill that would lift summertime restrictions on the sale of higher-ethanol fuel and tighten requirements for a biofuel blending exemption for small refineries.

  • May 14, 2026

    Med Device Co.'s CEO Touted Growth, Netted $39M, Suit Says

    Medical device maker Integer Holdings Corp.'s former CEO overstated growth prospects of a manufacturing program for the company's electrophysiology business, inflating the firm's stock price and allowing him to reap a nearly $39 million "windfall net profit," according to an investor's derivative lawsuit in Texas federal court.

  • May 14, 2026

    Albertsons Not Covered In Opioid Litigation, Del. Judge Says

    Albertsons isn't entitled to defense or indemnity for more than 100 suits accusing the pharmacy and grocery chain of fueling the opioid epidemic, a Delaware state court ruled, tracking the state high court's rulings in nearly identical disputes involving Rite Aid and CVS.

  • May 14, 2026

    Insider Trading Case Shows BigLaw Associate Vetting Gaps

    A BigLaw attorney who was able to move through three major firms while allegedly orchestrating a massive insider trading scheme may have been aided by relatively loose hiring practices for associates that firms may consider strengthening moving forward, recruiting experts told Law360.

  • May 14, 2026

    Fortive, Subsidiary Seek Early Win In Wrongful Firing Suit

    Technology company Fortive and a medical equipment subsidiary asked a Colorado federal judge for an early win in a former regional sales director's lawsuit alleging she was fired for raising concerns about compliance with anti-kickback rules, contending the subsidiary terminated her due to a restructuring and that Fortive wasn't her employer.

  • May 14, 2026

    High Court Maintains Abortion Pill Access Amid Circuit Appeal

    The U.S. Supreme Court on Thursday extended a stay preserving telehealth access to the abortion medication mifepristone while the Fifth Circuit weighs a challenge to the mail-order distribution of the pill.

  • May 14, 2026

    Takeda Cashed In From Delay Of Generic IBS Drug, Jury Told

    Drug buyers urged a Massachusetts federal jury on Thursday to find that Takeda Pharmaceuticals conspired with another drugmaker to keep a generic version of anticonstipation drug Amitiza off the market in order to boost its own profits. 

  • May 14, 2026

    BeiGene Must Face AbbVie's Chemical Trade Secret Claims

    An Illinois federal judge has denied oncological research company BeiGene's request to escape claims from AbbVie Inc. that it poached a retired scientist to obtain trade secrets related to a certain chemical compound, saying BeiGene failed to back up its arguments.

Expert Analysis

  • Trans Care Enforcement Landscape Is Evolving Quickly

    Author Photo

    The recent coordinated federal effort to reshape pediatric gender-affirming care through enforcement and funding pressure has created a rapidly evolving regulatory environment marked by shifting risk assessments and potential downstream market effects for healthcare institutions and life sciences companies, say attorneys at Arnall Golden.

  • Series

    Playing Piano Makes Me A Better Lawyer

    Author Photo

    Playing piano and practicing law share many parallels relating to managing complexity: Just as hearing an entire musical passage in my head allows me to reliably deliver the message, thinking about the audience's impression helps me create a legal narrative that keeps the reader engaged, says Michael Shepherd at Fish & Richardson.

  • 3 Cases Highlight SEC Distinction Between Exec, Co. Liability

    Author Photo

    Three recent enforcement actions against Spero Therapeutics, Lottery.com and Archer-Daniels-Midland demonstrate that while public companies are subject to liability for misrepresentations, the U.S. Securities and Exchange Commission is focused on individual liability when disclosure violations involve so-called half-truths, say attorneys at Cooley.

  • AI-Generated Doc Ruling Guides Attys On Privilege Risks

    Author Photo

    A New York federal court's ruling, in U.S. v. Heppner, that documents created by a defendant using an artificial intelligence tool were not privileged, can serve as a guide to attorneys for retaining attorney-client or work-product privilege over client documents created with AI, say attorneys at Sher Tremonte.

  • The Law Firm Merger Diaries: Leadership Strategy After Day 1

    Author Photo

    For law firm leaders, ensuring a newly combined law firm lives up to its promise, both in its first days of operation and well after, includes tough decisions, clear and specific communication, and cheerleading, says Peter Michaud at Ballard Spahr.

  • Record FCA Recoveries Signal Intensified Healthcare Focus

    Author Photo

    In its recently released False Claims Act statistics, the U.S. government's emphasis on record healthcare recoveries and government-initiated healthcare matters last year indicates robust enforcement ahead, though the administration's focus on current policy objectives also extends beyond the healthcare sector, say attorneys at Epstein Becker.

  • Fed. Circ. In Jan.: On The Validity Of Expert Testimony

    Author Photo

    The Federal Circuit's recent decision in Barry v. DePuy, addressing whether expert testimony is admissible even if it does not strictly adhere to the court's claim construction, suggests that exclusion via a Daubert motion is appropriate only when the line to improper testimony is clearly crossed, say attorneys at Knobbe Martens.

  • Calif.'s Civility Push Shows Why Professionalism Is Vital

    Author Photo

    The California Bar’s campaign against discourteous behavior by attorneys, including a newly required annual civility oath, reflects a growing concern among states that professionalism in law needs shoring up — and recognizes that maintaining composure even when stressed is key to both succeeding professionally and maintaining faith in the legal system, says Lucy Wang at Hinshaw.

  • A Potential Shift In FDA's Approach To Drug Trial Design

    Author Photo

    Recent guidance released by the U.S. Food and Drug Administration clarifying how Bayesian approaches — which combine prior knowledge with new data — may be used in clinical trials reflects the agency's continued interest in innovative trial designs that may accelerate drug approvals, say attorneys at Alston & Bird.

  • Series

    Trivia Competition Makes Me A Better Lawyer

    Author Photo

    Playing trivia taught me to quickly absorb information and recognize when I've learned what I'm expected to know, training me in the crucial skills needed to be a good attorney, and reminding me to be gracious in defeat, says Jonah Knobler at Patterson Belknap.

  • What FDA Guidance Means For Future Of Health Software

    Author Photo

    Two significant final guidance documents released by the U.S. Food and Drug Administration last month reflect a targeted effort to ease innovation friction around specific areas, including singular clinical decision support recommendations and sensor-based wearables, while maintaining established regulatory boundaries, say attorneys at Covington.

  • Opinion

    Federal Preemption In AI And Robotics Is Essential

    Author Photo

    Federal preemption offers a unified front at a decisive moment that is essential for safeguarding America's economic edge in artificial intelligence and robotics against global rivals, harnessing trillions of dollars in potential, securing high-skilled jobs through human augmentation, and defending technological sovereignty, says Steven Weisburd at Shook Hardy.

  • Series

    Law School's Missed Lessons: What Cross-Selling Truly Takes

    Author Photo

    Early-career attorneys may struggle to introduce clients to practitioners in other specialties, but cross-selling becomes easier once they know why it’s vital to their first years of practice, which mistakes to avoid and how to anticipate clients' needs, say attorneys at Moses & Singer.

  • Drafting Tech Patents After USPTO's Eligibility Memos

    Author Photo

    Two recent U.S. Patent and Trademark Office memos on subject matter eligibility declarations provide an evidentiary playbook for artificial intelligence and software patent applications, highlighting how targeted, stand‑alone SMEDs that present objective, claim‑anchored facts can improve patent application outcomes, say attorneys at Reed Smith.

  • How State FCA Activity May Affect Civil Fraud Enforcement

    Author Photo

    A growing trend of state attorneys general enforcing their False Claims Act analogues independently of the U.S. Department of Justice carries potential repercussions for civil fraud enforcement and qui tam litigation considerations, say Li Yu at Bernstein Litowitz, Ellen London at London & Naor and Gwen Stamper at Vogel Slade.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.